PharmaMar gets $200M upfront payment from Jazz for lurbinectedin

29 January 2020
pharmamarbig

Spanish drugmaker PharmaMar’s (MC: PHM) shares rose as much as 6.3% to 4.23 euros this morning, after it announced receipt of the upfront payment of $200 million from the agreement signed with Jazz Pharmaceuticals (Nasdaq: JAZZ) on 19 December 19, 2019.

This license agreement for the commercialization of lurbinectedin in the USA became effective with the expiration of the Hart-Scott-Rodino waiting period.

Under the terms of the deal worth up to $1 billion in total, PharmaMar is also eligible to receive, in the following months, potential regulatory milestone payments of up to $250 million on the achievement of accelerated and/or full regulatory approval of lurbinectedin by US Food and Drug Administration within certain timelines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical